Biotech Values

[DewDiligence]

MNTA/TEVA—A good fishing question for an analyst to ask Teva at the next opportunity: "Has the FDA inspected your enoxaparin manufacturing facilities?"

As of 7/27/10 (the date of Teva’s 2Q10 CC), we may presume that such inspections had not yet occurred. If they had, Teva’s Bill Marth would almost certainly have said so during the CC.